vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Urban Edge Properties (UE). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $132.6M, roughly 1.0× Urban Edge Properties). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 17.1%, a 18.4% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 12.2%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 11.6%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Urban Edge Properties is a publicly traded real estate investment trust (REIT) that owns, operates, and develops high-quality retail and mixed-use properties, primarily located in densely populated urban and suburban markets across the United States. Its portfolio covers grocery-anchored shopping centers, lifestyle outlets, and community-focused commercial assets.
ADMA vs UE — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $132.6M |
| Net Profit | $49.4M | $22.6M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | — |
| Net Margin | 35.5% | 17.1% |
| Revenue YoY | 18.4% | 12.2% |
| Net Profit YoY | -55.9% | -6.7% |
| EPS (diluted) | $0.20 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $132.6M | ||
| Q4 25 | $139.2M | $119.6M | ||
| Q3 25 | $134.2M | $120.1M | ||
| Q2 25 | $122.0M | $114.1M | ||
| Q1 25 | $114.8M | $118.2M | ||
| Q4 24 | $117.5M | $116.4M | ||
| Q3 24 | $119.8M | $112.4M | ||
| Q2 24 | $107.2M | $106.5M |
| Q1 26 | — | $22.6M | ||
| Q4 25 | $49.4M | $12.4M | ||
| Q3 25 | $36.4M | $14.9M | ||
| Q2 25 | $34.2M | $58.0M | ||
| Q1 25 | $26.9M | $8.2M | ||
| Q4 24 | $111.9M | $30.1M | ||
| Q3 24 | $35.9M | $9.1M | ||
| Q2 24 | $32.1M | $30.8M |
| Q1 26 | — | — | ||
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 45.1% | 11.3% | ||
| Q3 25 | 38.0% | 13.4% | ||
| Q2 25 | 35.1% | 53.9% | ||
| Q1 25 | 30.4% | 7.6% | ||
| Q4 24 | 32.6% | 27.6% | ||
| Q3 24 | 33.1% | 8.9% | ||
| Q2 24 | 36.6% | 30.6% |
| Q1 26 | — | 17.1% | ||
| Q4 25 | 35.5% | 10.4% | ||
| Q3 25 | 27.1% | 12.4% | ||
| Q2 25 | 28.1% | 50.8% | ||
| Q1 25 | 23.4% | 6.9% | ||
| Q4 24 | 95.2% | 25.9% | ||
| Q3 24 | 30.0% | 8.1% | ||
| Q2 24 | 29.9% | 28.9% |
| Q1 26 | — | $0.18 | ||
| Q4 25 | $0.20 | $0.09 | ||
| Q3 25 | $0.15 | $0.12 | ||
| Q2 25 | $0.14 | $0.46 | ||
| Q1 25 | $0.11 | $0.07 | ||
| Q4 24 | $0.45 | $0.25 | ||
| Q3 24 | $0.15 | $0.07 | ||
| Q2 24 | $0.13 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $50.0M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $1.4B |
| Total Assets | $624.2M | $3.4B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $50.0M | ||
| Q4 25 | $87.6M | $48.9M | ||
| Q3 25 | $61.4M | $77.8M | ||
| Q2 25 | $90.3M | $53.0M | ||
| Q1 25 | $71.6M | $48.0M | ||
| Q4 24 | $103.1M | $41.4M | ||
| Q3 24 | $86.7M | $67.9M | ||
| Q2 24 | $88.2M | $78.6M |
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $477.3M | $1.4B | ||
| Q3 25 | $431.2M | $1.4B | ||
| Q2 25 | $398.3M | $1.4B | ||
| Q1 25 | $373.4M | $1.4B | ||
| Q4 24 | $349.0M | $1.4B | ||
| Q3 24 | $231.9M | $1.3B | ||
| Q2 24 | $188.3M | $1.3B |
| Q1 26 | — | $3.4B | ||
| Q4 25 | $624.2M | $3.3B | ||
| Q3 25 | $568.7M | $3.3B | ||
| Q2 25 | $558.4M | $3.3B | ||
| Q1 25 | $510.6M | $3.3B | ||
| Q4 24 | $488.7M | $3.3B | ||
| Q3 24 | $390.6M | $3.2B | ||
| Q2 24 | $376.4M | $3.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $39.1M |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | 1.5% |
| Cash ConversionOCF / Net Profit | 0.72× | 1.73× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $39.1M | ||
| Q4 25 | $35.6M | $182.7M | ||
| Q3 25 | $13.3M | $55.7M | ||
| Q2 25 | $21.1M | $43.5M | ||
| Q1 25 | $-19.7M | $32.6M | ||
| Q4 24 | $50.2M | $153.2M | ||
| Q3 24 | $25.0M | $36.6M | ||
| Q2 24 | $45.6M | $41.2M |
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | $81.8M | ||
| Q3 25 | $-1.1M | $26.1M | ||
| Q2 25 | $18.7M | $19.6M | ||
| Q1 25 | $-24.4M | $11.9M | ||
| Q4 24 | $47.5M | $42.5M | ||
| Q3 24 | $24.0M | $12.2M | ||
| Q2 24 | $43.6M | $19.9M |
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | 68.4% | ||
| Q3 25 | -0.8% | 21.7% | ||
| Q2 25 | 15.3% | 17.2% | ||
| Q1 25 | -21.2% | 10.0% | ||
| Q4 24 | 40.4% | 36.6% | ||
| Q3 24 | 20.0% | 10.8% | ||
| Q2 24 | 40.7% | 18.6% |
| Q1 26 | — | 1.5% | ||
| Q4 25 | 0.8% | 84.4% | ||
| Q3 25 | 10.7% | 24.6% | ||
| Q2 25 | 2.0% | 20.9% | ||
| Q1 25 | 4.1% | 17.5% | ||
| Q4 24 | 2.3% | 95.1% | ||
| Q3 24 | 0.9% | 21.7% | ||
| Q2 24 | 1.9% | 20.1% |
| Q1 26 | — | 1.73× | ||
| Q4 25 | 0.72× | 14.71× | ||
| Q3 25 | 0.36× | 3.73× | ||
| Q2 25 | 0.62× | 0.75× | ||
| Q1 25 | -0.73× | 3.97× | ||
| Q4 24 | 0.45× | 5.09× | ||
| Q3 24 | 0.70× | 4.03× | ||
| Q2 24 | 1.42× | 1.34× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
UE
| Rental revenue | $124.2M | 94% |
| Other | $8.4M | 6% |
